Advertisement

Relatlimab and Nivolumab vs Nivolumab Alone in Untreated Advanced Melanoma
Posted: 01/11/2022 | By: Sarah Campen, PharmD

Question 1 of 5

Relatlimab improved progression-free survival in combination with nivolumab compared with PD-1 inhibition alone in patients with previously untreated metastatic or unresectable melanoma. How does relatlimab work?

Choose 1

A
Blocks PD-1, reversing inhibitory signals transmitted to T cells and allowing metabolic reprogramming of T cells
B
Inhibits CTLA-4, diminishing signaling through the co-stimulatory receptor CD28
C
Binds to LAG-3, restoring the effector function of exhausted T cells
D
Inhibits both PD-1 and LAG-3, providing dual checkpoint inhibition

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage